Alpine Immune Sciences, Inc. (ALPN) financial statements (2021 and earlier)

Company profile

Business Address 188 EAST BLAINE ST., SUITE 200
SEATTLE, WA 98102
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1064152816187
Cash and cash equivalents35161182425
Short-term investments712442733762
Restricted cash and investments 0    
Receivables0000  
Prepaid expense1000  
Deferred costs 00   
Other undisclosed current assets110110
Total current assets:1074254836288
Noncurrent Assets
Operating lease, right-of-use asset910
Property, plant and equipment221100
Long-term investments and receivables26     
Long-term investments26     
Intangible assets, net (including goodwill)   1  
Intangible assets, net (excluding goodwill)   1  
Restricted cash and investments0000  
Other undisclosed noncurrent assets    00
Total noncurrent assets:37121300
TOTAL ASSETS:1445455856288
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities676143
Accounts payable122021
Accrued liabilities654000
Employee-related liabilities    22
Deferred revenue321
Debt3021  
Deferred rent credit  0
Deferred revenue and credits0  
Other undisclosed current liabilities1   32
Total current liabilities:4198264
Noncurrent Liabilities
Long-term debt and lease obligation191624  
Long-term debt, excluding current maturities8524  
Operating lease, liability1211
Liabilities, other than long-term debt21  0  
Deferred revenue and credits0  
Deferred revenue21 
Deferred tax liabilities, net 0  
Total noncurrent liabilities:411624  
Total liabilities:822510664
Stockholders' equity
Stockholders' equity attributable to parent, including:622945795583
Common stock    00
Additional paid in capital1781179188236232
Accumulated other comprehensive income (loss)00(0)(0)(0)0
Accumulated deficit(116)(88)(46)(9)(180)(149)
Other undisclosed stockholders' equity attributable to parent0000  
Total stockholders' equity:622945795583
TOTAL LIABILITIES AND EQUITY:1445455856288

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenue, net2  
Gross profit:9212  
Operating expenses(38)(45)(39)(17)(32)(23)
Operating loss:(29)(44)(38)(15)(32)(23)
Nonoperating income22 7 0
Investment income, nonoperating01 7  
Other nonoperating income11    
Interest and debt expense(1)(0)(0)(0)  
Loss from continuing operations before equity method investments, income taxes:(28)(42)(38)(9)(32)(23)
Other undisclosed income from continuing operations before income taxes  11  
Loss from continuing operations before income taxes:(28)(42)(37)(8)(32)(23)
Income tax benefit0 00  
Net loss:(28)(42)(36)(8)(32)(23)
Other undisclosed net income attributable to parent    0 
Net loss available to common stockholders, diluted:(28)(42)(36)(8)(31)(23)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(28)(42)(36)(8)(32)(23)
Comprehensive loss:(28)(42)(36)(8)(32)(23)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent000(0)00
Comprehensive loss, net of tax, attributable to parent:(28)(42)(36)(8)(31)(23)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: